HEALTHCARE
Global Immunotherapy Drugs Market - Industry Trends and Forecast to 2032
REPORT OVERVIEW
Global Immunotherapy Drugs Market, By Type (Antibody Drugs, Inhibitor Drugs, Interferons and Interleukins, Cancer Vaccines, and Others), Application (Cancer, Autoimmune and Inflammatory Diseases, Hematology, Osteology, Neurology, and Others), Route of Administration (Intravenous, Subcutaneous, and Others), End Use (Hospitals, Long-Term Care Facilities, and Others), Region (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2032.
Market Insights
Market Dynamics
- Advances in cancer research and technology
- Rising incidence of cancer
- Expensive treatments
- Healthcare infrastructure limitations
- Cost reduction and access improvement
- Development of new drug classes
- Managing and mitigating side effects
- Scientific and clinical uncertainties
SEGMENTATION
- Type
- Antibody Drugs
- Inhibitor Drugs
- Interferons and Interleukins
- Cancer Vaccines
- Others
- Application
- Cancer
- Autoimmune and Inflammatory Diseases
- Hematology
- Osteology
- Neurology
- Others
- Route of Administration
- Intravenous
- Subcutaneous
- Others
- End Use
- Hospitals
- Long-Term Care Facilities
- Others
KEY MARKET PLAYERS
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
- F. Hoffman-La Roche Ltd.
- Pfizer Inc.
- AstraZeneca
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Sanofi
- GSK PLC
- Abbvie Inc.
Table OF CONTENTS
- SECTION 1 - INTRODUCTION
- 1.1 Taxonomy
- 1.2 Market Overview
- 1.3 Currency and Limitations
- 1.3.1 Currency
- 1.3.2 Limitations
- 1.4 Key Competitors
- SECTION 2 - RESEARCH METHODOLOGY
- 2.1 Research Approach
- 2.2 Data Collection and Validation
- 2.2.1 Secondary Research
- 2.2.2 Primary Research
- 2.3 Market Assessment
- 2.3.1 Market Size Estimation
- 2.3.2 Bottom-up Approach
- 2.3.3 Top-down Approach
- 2.3.4 Growth Forecast
- 2.4 Market Study Assumptions
- 2.5 Data Sources
- SECTION 3 - EXECUTIVE SUMMARY
- 3.1 Global Immunotherapy Drugs Market, by Type
- 3.2 Global Immunotherapy Drugs Market, by Application
- 3.3 Global Immunotherapy Drugs Market, by Route of Administration
- 3.4 Global Immunotherapy Drugs Market, by End Use
- 3.5 Global Immunotherapy Drugs Market, by Geography
- 3.6 Market Position Grid
- SECTION 4 - PREMIUM INSIGHTS
- 4.1 Regulatory Framework
- 4.1.1 Standards
- 4.1.2 Regulatory Landscape
- 4.2 Value Chain Analysis
- 4.3 Supply Chain Analysis
- 4.4 COVID-19 Impact
- 4.5 Russia-Ukraine War Impact
- 4.6 PORTER's Five Force Analysis
- 4.7 PESTLE Analysis
- 4.8 SWOT Analysis
- 4.9 Go to Market Strategy
- 4.10 Opportunity Orbit
- 4.11 Multivariate Modelling
- 4.12 Pricing Analysis
- SECTION 5 - MARKET DYNAMICS
- 5.1 Trends
- 5.1.1 Combination therapies
- 5.1.2 Personalized and precision medicine
- 5.1.3 Trend 3
- 5.2 Drivers
- 5.2.1 Advances in cancer research and technology
- 5.2.2 Rising incidence of cancer
- 5.2.3 Driver 3
- 5.2.4 Driver 4
- 5.3 Restraints
- 5.3.1 Expensive treatments
- 5.3.2 Healthcare infrastructure limitations
- 5.3.3 Restraint 3
- 5.4 Opportunities
- 5.4.1 Cost reduction and access improvement
- 5.4.2 Development of new drug classes
- 5.4.3 Opportunity 3
- 5.4.4 Opportunity 4
- 5.5 Challenges
- 5.5.1 Managing and mitigating side effects
- 5.5.2 Scientific and clinical uncertainties
- 5.5.3 Challenge 3
- SECTION 6 - GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE
- 6.1 Type Summary
- 6.2 Market Attractive Index
- 6.3 Global Immunotherapy Drugs Market, by Type (2019-2032)
- SECTION 7 - GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION
- 7.1 Application Summary
- 7.2 Market Attractive Index
- 7.3 Global Immunotherapy Drugs Market, by Application (2019-2032)
- SECTION 8 - GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION
- 8.1 Route of Administration Summary
- 8.2 Market Attractive Index
- 8.3 Global Immunotherapy Drugs Market, by Route of Administration (2019-2032)
- SECTION 9 - GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END USE
- 9.1 End Use Summary
- 9.2 Market Attractive Index
- 9.3 Global Immunotherapy Drugs Market, by End Use (2019-2032)
- SECTION 10 - GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY GEOGRAPHY
- 10.1 Regional Summary
- 10.2 Market Attractive Index
- 10.3 Global Immunotherapy Drugs Market, by Geography (2019-2032)
- SECTION 11 - NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET
- 11.1 North America Summary
- 11.2 Market Attractive Index
- 11.3 North America Immunotherapy Drugs Market, by Type (2019-2032)
- 11.4 North America Immunotherapy Drugs Market, by Application (2019-2032)
- 11.5 North America Immunotherapy Drugs Market, by Route of Administration (2019-2032)
- 11.6 North America Immunotherapy Drugs Market, by End Use (2019-2032)
- 11.7 North America Immunotherapy Drugs Market, by Country (2019-2032)
- 11.7.1 U.S.
- 11.7.2 Canada
- 11.7.3 Mexico
- 11.7.4 Rest of North America
- SECTION 12 - EUROPE IMMUNOTHERAPY DRUGS MARKET
- 12.1 Europe Summary
- 12.2 Market Attractive Index
- 12.3 Europe Immunotherapy Drugs Market, by Type (2019-2032)
- 12.4 Europe Immunotherapy Drugs Market, by Application (2019-2032)
- 12.5 Europe Immunotherapy Drugs Market, by Route of Administration (2019-2032)
- 12.6 Europe Immunotherapy Drugs Market, by End Use (2019-2032)
- 12.7 Europe Immunotherapy Drugs Market, by Country (2019-2032)
- 12.7.1 Germany
- 12.7.2 U.K.
- 12.7.3 France
- 12.7.4 Italy
- 12.7.5 Spain
- 12.7.6 Russia
- 12.7.7 The Netherlands
- 12.7.8 Belgium
- 12.7.9 Turkey
- 12.7.10 Rest of Europe
- SECTION 13 - ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET
- 13.1 Asia-Pacific Summary
- 13.2 Market Attractive Index
- 13.3 Asia-Pacific Immunotherapy Drugs Market, by Type (2019-2032)
- 13.4 Asia-Pacific Immunotherapy Drugs Market, by Application (2019-2032)
- 13.5 Asia-Pacific Immunotherapy Drugs Market, by Route of Administration (2019-2032)
- 13.6 Asia-Pacific Immunotherapy Drugs Market, by End Use (2019-2032)
- 13.7 Asia-Pacific Immunotherapy Drugs Market, by Country (2019-2032)
- 13.7.1 China
- 13.7.2 India
- 13.7.3 Japan
- 13.7.4 South Korea
- 13.7.5 Singapore
- 13.7.6 Malaysia
- 13.7.7 Australia
- 13.7.8 Thailand
- 13.7.9 Philippines
- 13.7.10 Rest of Asia-Pacific
- SECTION 14 - SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET
- 14.1 South America Summary
- 14.2 Market Attractive Index
- 14.3 South America Immunotherapy Drugs Market, by Type (2019-2032)
- 14.4 South America Immunotherapy Drugs Market, by Application (2019-2032)
- 14.5 South America Immunotherapy Drugs Market, by Route of Administration (2019-2032)
- 14.6 South America Immunotherapy Drugs Market, by End Use (2019-2032)
- 14.7 South America Immunotherapy Drugs Market, by Country (2019-2032)
- 14.7.1 Brazil
- 14.7.2 Argentina
- 14.7.3 Chile
- 14.7.4 Colombia
- 14.7.5 Rest of South America
- SECTION 15 - MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET
- 15.1 Middle East and Africa Summary
- 15.2 Market Attractive Index
- 15.3 Middle East and Africa Immunotherapy Drugs Market, by Type (2019-2032)
- 15.4 Middle East and Africa Immunotherapy Drugs Market, by Application (2019-2032)
- 15.5 Middle East and Africa Immunotherapy Drugs Market, by Route of Administration (2019-2032)
- 15.6 Middle East and Africa Immunotherapy Drugs Market, by End Use (2019-2032)
- 15.7 Middle East and Africa Immunotherapy Drugs Market, by Country (2019-2032)
- 15.7.1 Kingdom of Saudi Arabia
- 15.7.2 South Africa
- 15.7.3 U.A.E.
- 15.7.4 Egypt
- 15.7.5 Rest of Middle East and Africa
- SECTION 16 - COMPANY SHARE ANALYSIS
- 16.1 Global Immunotherapy Drugs Market, Company Share Analysis
- 16.2 North America Immunotherapy Drugs Market, Company Share Analysis
- 16.3 Europe Immunotherapy Drugs Market, Company Share Analysis
- 16.4 Asia-Pacific Immunotherapy Drugs Market, Company Share Analysis
- SECTION 17 - COMPANY PROFILES
- 17.1 Merck & Co., Inc.
- 17.1.1 Company Snapshot
- 17.1.2 Financial Overview
- 17.1.3 Product Portfolio
- 17.1.4 Recent Developments
- 17.2 Johnson & Johnson Services, Inc.
- 17.2.1 Company Snapshot
- 17.2.2 Financial Overview
- 17.2.3 Product Portfolio
- 17.2.4 Recent Developments
- 17.3 F. Hoffman-La Roche Ltd.
- 17.3.1 Company Snapshot
- 17.3.2 Financial Overview
- 17.3.3 Product Portfolio
- 17.3.4 Recent Developments
- 17.4 Pfizer Inc.
- 17.4.1 Company Snapshot
- 17.4.2 Financial Overview
- 17.4.3 Product Portfolio
- 17.4.4 Recent Developments
- 17.5 AstraZeneca
- 17.5.1 Company Snapshot
- 17.5.2 Financial Overview
- 17.5.3 Product Portfolio
- 17.5.4 Recent Developments
- 17.6 Novartis AG
- 17.6.1 Company Snapshot
- 17.6.2 Financial Overview
- 17.6.3 Product Portfolio
- 17.6.4 Recent Developments
- 17.7 Takeda Pharmaceutical Company Limited
- 17.7.1 Company Snapshot
- 17.7.2 Financial Overview
- 17.7.3 Product Portfolio
- 17.7.4 Recent Developments
- 17.8 Sanofi
- 17.8.1 Company Snapshot
- 17.8.2 Financial Overview
- 17.8.3 Product Portfolio
- 17.8.4 Recent Developments
- 17.9 GSK PLC
- 17.9.1 Company Snapshot
- 17.9.2 Financial Overview
- 17.9.3 Product Portfolio
- 17.9.4 Recent Developments
- 17.10 Abbvie Inc.
- 17.10.1 Company Snapshot
- 17.10.2 Financial Overview
- 17.10.3 Product Portfolio
- 17.10.4 Recent Developments
- SECTION 18 - RELATED REPORTS
- SECTION 19 - DISCLAIMER
RESEARCH METHODOLOGY
RESEARCH AND DATA COLLECTION
- Research articles published on Technium
- Science and MDPI
- Research publications by government approved associations and societies
DATA PRE-PROCESSING
The term "data pre-processing" refers to the collection of procedures and methods used to clean, modify, and make ready for analysis the raw data gathered during research and data collection. The completion of this phase is necessary to guarantee that the data are reliable, consistent, and appropriate for statistical analysis and other data-driven tasks. The data pre-processing ensures that the information gathered from research and data collection is comparable and expressed in standard units, by the integration of missing data pointers and algorithmic approaches.
MODELING AND FORECASTING
QUALITY ASSURANCE AND OUTPUT
Quality assurance and output involves the process of validation, adjustments, further publications of key market indicators. Extensive plausibility and consistency tests are performed on derived time series to ensure the high degree of quality of our market analysis. This quality assurance procedure also includes rigorous inspection, validation, and editing by an experienced management team to assure the dependability of the published data.